<DOC>
	<DOCNO>NCT00461773</DOCNO>
	<brief_summary>The purpose study evaluate objective response rate combination letrozole ( Femara ) bevacizumab ( Avastin ) give preoperatively postmenopausal patient hormone sensitive breast cancer .</brief_summary>
	<brief_title>Randomized Phase II Study Preoperative Letrozole ( Femara ) Combination With Avastin Hormone Receptor Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Histologically confirm operable potentially operable invasive breast adenocarcinoma clinically palpable measurable Age ≥ 18 year Clinical Stage T24 , N03 , M0 ( Stage IIIII ) Postmenopausal define Age ≥ 60 year and/or Age &gt; 45 year amenorrhea 12 month intact uterus and/or History bilateral oophorectomy and/or FSH estradiol level postmenopausal range ECOG PS 0 , 1 Unifocal disease ER and/or PR positive Adequate hematological , renal , hepatic function Absolute neutrophil count ≥ 1,500/µL Platelet count ≥ 100,000/µL creatinine ≤ 1.5 mg/dL Serum total bilirubin ≤ 1.5 mg/dL Alkaline phosphatase ≤ 3X ULN reference lab SGOT/SGPT ≤ 3X ULN reference lab Patients legal representative must able read , understand provide inform consent participate trial Use effective mean contraception ( men woman ) subject childbearing potential Prior history and/or therapy invasive breast cancer ( include chemotherapy , radiation , hormonal therapy include AIs , tamoxifen , raloxifene , fulvestrant antiestrogen/SERM ) Clinically significant cardiovascular disease , EF &lt; 50 % Known CNS disease History deep vein thrombosis pulmonary embolism Proteinuria screening demonstrate either Urine protein : creatinine ( UPC ) ratio ≥ 1.0 screening OR Urine dipstick proteinuria ≥ 2+ ( patient discover ≥2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate ≤ 1g protein 24 hour eligible ) . Presence nonhealing wound fracture Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored bevacizumab cancer study Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) Any prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix E ) History myocardial infarction unstable angina within 12 month prior study enrollment Any history stroke transient ischemic attack time Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) Symptomatic peripheral vascular disease Evidence bleed diathesis coagulopathy Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 Core biopsy minor surgical procedure fine needle aspiration core biopsy within 7 day prior Day 0 Pregnant ( positive pregnancy test ) lactating . Use effective mean contraception ( men woman ) subject childbearing potential mandatory History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 Known hypersensitivity component bevacizumab letrozole Inability comply study and/or followup procedure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Neoadjuvant treatment</keyword>
</DOC>